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for a given (single) cell. Therefore, we have implemented an
approach to interrogate the complexity of bulk populations of
manufactured CAR+ T cells, so that the contribution of indi-
vidual cells to theoverall anti-tumoreffect canbe ascertained.
CD19-speciﬁc CAR+ T cells currently being used in clinical
trialswere analyzed at a single cell level using technology that
combines functional screening (cytotoxicity, cytokine pro-
duction)with theirmolecular proﬁles. BulkTcellswhich lysed
tumor targets at 28% (1:1; effector:target ratio) in a standard4
hour chromium lysis assaywereobservedat the single level to
lyse multiple targets and function as serial killers (Figure).
There was no correlation between IFN-g production and
cytolysis. T cells that participated in killing and/or cytokine
secretion were more susceptible to apoptosis than lympho-
cytes that did not participate in effector function. These data
highlight that deconstructing the heterogeneity of a bulk
population into individual cells can be used to determine
whether subsets of T cells can participate in serial killing. The
ability to serially image T-cell killing in massively parallel
arrays will enable investigators to design CAR molecules that
can support multi-hit kill kinetics. This lays the ground work
formore complex studies evaluating cytokine production and
genetic signatures of individual T cells bearing CAR species
that comprise the infusion product.186
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Allogeneic stem cell transplantation (AlloSCT) from HLA-
matched unaffected sibling donors (MSD) has been suc-
cessful for high-risk SCD, but only 14-18% of patients have
such a donor (Freed/Cairo et al, BMT, 2012). Alternate donors
include unrelated adult donors (URD) and umbilical cord
blood (UCB) donors (Cairo et al., BBMT, 2008). URD are
limited and unrelated UCB transplant results are poor (Rad-
hakrishnan K/Cairo et al., BBMT 2013, Kamani et al., BBMT,
2012). In a high-risk FHI TCD thalassemia study, 16/22 cases
engrafted without acute GVHD (aGVHD) and with 90%
overall survival. (Sodani et al., Blood, 2010). FHI TCD AlloSCT,
could expand the donor pool and improve outcomes for SCD.
This SCD consortium trial is investigating the safety, feasi-
bility, EFS, donor chimerism, graft failure, acute and chronic
GVHD, and infectious mortality after FHI TCD AlloSCT in
high-risk SCD patients (Figure 1).
Patients (2-20.99 yrs) without an 8/8 HLA MSD or URD and
who have 1 high-risk SCD feature are eligible. Patients
receive hydroxyurea (60mg/kg/d) and azathioprine (3mg/kg/
d x50d), ﬂudarabine (30mg/m2/d x5d), busulfan (3.2mg/kg/
d x4d), thiotepa (10mg/kg x1d), cyclophosphamide (50mg/kg
x4d), R-ATG (2mg/kg/d x4d), and TLI (500cGy) followed by
FHI T-cell depleted AlloSCT. Acute GVHD prophylaxis is.
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526-001
NYMC
10yrs/M 10/29/
12
Mother Pain Crises > 3
Abnormal TCD
None to date None +13 >99%/Day+180 99%/Day+180 Alive+332
526-002
NYMC
13yrs/F 2/19/13 Mother 2 strokes
Abnormal TCD
None to date None +9 92%/Day + 180 85%/Day +180 Alive +219
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esis- CD34-enriched cells; target dose of 10.0 x 106 CD34+
cells/kg with 2.0 x 105 CD3+ T cells/kg added back.
Two patients have received AlloSCTs to date. Pt. 1 is a 10yr _
with a history of abnormal Transcranial Dopplers andmultiple
VasoocclusiveCrises. Pt. 2 isa13yr\with twopreviousstrokes,
hypertransfusion and Moyamoya. Both utilized maternal do-
nors without complications, and had early myeloid engraft-
ment, 92% whole blood and  85%RBC donor chimerism, no
aGVHDor cGVHD, and are alivewithNED (Figure 2). Twomore
patients are undergoing conditioning.
Early results indicate FHI TCD AlloSCT is feasible in high-risk
SCD patients who lackMSD or URD. A larger cohort is needed
to assess long-term safety and outcomes (Supported by FDA
5R01FD004090-02 and a grant from Otsuka) (IND #14359
and NCT 01461837).187
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plantation (HSCT) signiﬁcant morbidity, mortality, and
ﬁnancial cost secondary to opportunistic infections remains.
Immune reconstitution prevents and treats infections. Select
academic facilities and biomedical companies infuse donor-
derived T cells selectively cultured on antigen, identiﬁed
based on desired T-cell receptor expression, or selected for
ability to generate gamma-interferon (g-IFN) . The “capture”
of T cells secreting g-IFN in response to stimulation with
antigen is rapid (T cells are available within hours of collec-
tion from donor) and independent of human leukocyte an-
tigen. The limitation of capturing these desired T cells using a
magnetic bi-speciﬁc reagent (that recognizes CD45 and g-
IFN) is the cumbersome and labor-intensive procedure
associated with using ﬁrst-generation CliniMACS device
from Miltenyi Biotec. We report the ﬁrst experience using
second generation CliniMACS Prodigy device to automate
production of T cells captured for their ability to generate g-
IFN in response to cytomegalovirus (CMV). Eight steady-state
apheresis products from CMV seropositive donors were
processed. Following activationwith PepTivator CMV pp65, T
cells secreting g-IFN were isolated in a closed, hands-free
system within 12 hours. Two donors failed to produce CMV-
speciﬁc T cells due to low starting number of CD3+g-IFN+ T
cells (<0.01%). There was an average of 0.07% g-IFN CD4+ T
cells (range 0.03-0.61%) prior to capture and an average of
62.2% (range 14.7-91.4%) after enrichment. The g-IFN CD8+ T
cells prior to enrichment was 0.43% (range 0.07-0.56%) and
89.36% (range 61.6-94.2%) after capture. This yielded an
average of 3x105 CD3+g-IFN+ Tcells. For a 70 kg adult and a 30
